Efficacy of Roxadustat for Secondary Hyperparathyroidism

Qiong Wu, Xiang‐Peng Liao, Qin Zou, Chen Ting Li, Yiyao CuiIndian 2024 · DOI

TL;DR

This study demonstrates that Roxadustat, an oral HIF-PHI, is significantly more effective than traditional erythropoietin (EPO) and iron therapy for managing Secondary Hyperparathyroidism (SHPT) in patients with chronic kidney disease. Beyond just treating anemia, Roxadustat was shown to suppress microinflammation and markedly improve patients' overall quality of life with a favorable safety profile.

What Problem Does This Paper Address?

Secondary Hyperparathyroidism (SHPT) is a frequent and severe complication of Chronic Kidney Disease (CKD). It is characterized by parathyroid hyperplasia and excessive secretion of intact Parathyroid Hormone (iPTH), leading to disrupted calcium and phosphate metabolism. For patients, this translates to bone pain, skin itching, muscle weakness, and potentially life-threatening ectopic calcification.

While current treatments like Vitamin D analogs, calcimimetics, and phosphate binders exist, they are often limited by narrow therapeutic windows, high costs, or unbearable side effects. There is a pressing need for therapies that can simultaneously address the hormonal imbalances of SHPT and the systemic inflammation and anemia that typically accompany it.

Methods

The researchers conducted a comparative clinical study involving 65 patients with SHPT between May 2022 and May 2023. The cohort was divided into two groups:

  • Control Group (n=30): Received standard therapy consisting of oral iron polysaccharide complex capsules (150 mg/day) and subcutaneous injections of erythropoietin (EPO) (10,000 units/week).
  • Observation Group (n=35): Received Roxadustat (100 mg) orally three times a week for 12 weeks.

The study evaluated several endpoints:

  1. Clinical Efficacy: Based on the recovery of clinical symptoms and normalization of iPTH, blood calcium, and blood phosphorus.
  2. Safety: Monitoring adverse events like fatigue, nausea, and hypercalcemia.
  3. Biochemical Indices: Measuring Red Blood Cell (RBC) count, Hematocrit (HCT), and Hemoglobin (Hb).
  4. Inflammatory Markers: Measuring C-Reactive Protein (CRP), Beta 2-Microglobulin (β2MG), and Interleukin-6 (IL-6) via ELISA.
  5. Quality of Life: Assessed using the WHOQOL-BREF scale across physical, psychological, social, and environmental domains.

Datasets

The study relied on a primary clinical dataset of 65 patients diagnosed with SHPT at the First Peoples’ Hospital of Chenzhou. Inclusion criteria required PTH levels between 300-800 pg/ml and Hemoglobin levels between 60-110 mmHg. No external benchmarks or secondary datasets were used.

Key Insights and Ideas

  • Multifaceted Mechanism: Roxadustat is a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI). Unlike EPO, which just stimulates red blood cell production, Roxadustat mimics the body's natural response to low oxygen. This promotes endogenous EPO production and improves iron homeostasis by inhibiting hepcidin.
  • Breaking the SHPT Cascade: A critical insight is that Roxadustat helps inhibit Fibroblast Growth Factor 23 (FGF23) levels. FGF23 is a key driver in the pathological "vicious cycle" of SHPT; by suppressing it, the drug addresses the root hormonal dysfunction rather than just the symptoms.
  • Anti-Inflammatory Synergy: The study found that Roxadustat significantly lowered systemic inflammatory markers (CRP, IL-6). In CKD patients, chronic inflammation often causes "EPO resistance." By reducing this inflammation, Roxadustat makes the body's own erythropoiesis more efficient.

Key Results

  • Superior Efficacy: The total effective rate for the Roxadustat group was 91.43%, compared to only 70.00% in the control group ($p < 0.05$).
  • Improved Blood Profiles: Patients on Roxadustat showed significantly higher increases in RBC count, HCT, and Hb levels compared to those on traditional EPO/iron therapy.
  • Inflammation Suppression: Post-treatment levels of CRP, β2MG, and IL-6 were significantly lower in the Roxadustat group than in the control group.
  • Enhanced Quality of Life: Roxadustat patients reported significantly higher scores across all four WHO quality-of-life domains (Physiology, Psychology, Social Relationship, and Environment).
  • Safety: The incidence of adverse events was lower in the Roxadustat group (11.43%) compared to the control group (16.67%), though this difference was not statistically significant, indicating comparable safety.

Limitations and Future Work

The authors acknowledge that while the results are promising, the study has limitations:

  • Sample Size: The cohort of 65 patients is relatively small for a clinical study.
  • Study Duration: The 12-week follow-up period is short; long-term efficacy and safety (especially regarding potential cardiovascular risks associated with HIF stabilizers) need further investigation.
  • Single-Center Study: The data comes from a single hospital, which may limit the generalizability of the findings across different populations.

Future research should focus on larger, multi-center randomized controlled trials with longer follow-up periods to confirm these benefits and further explore the molecular pathways through which Roxadustat modulates the parathyroid-bone axis.

Summary updated

Abstract

This study summarizes the efficacy of roxadustat for secondary hyperparathyroidism. 65 individuals with secondary hyperparathyroidism were selected between May 2022 and May 2023 and were divided into control (n=30) and observation groups (n=35). The control group was treated with iron polysaccharide complex capsules+erythropoietin while the observation group was given roxadustat. Comparative analysis was conducted in terms of efficacy, drug safety which included fatigue, nausea and vomiting, myodynia and hypercalcemia. Further, serum biochemical indices like red blood cell count, hematocrit value and hemoglobin concentration were observed and compared. Then, microinflammation indicators like C-reactive protein, beta 2-microglobulin and interleukin-6 were also evaluated. Finally, the quality of life according to the World Health Organization quality of life was evaluated. The results revealed markedly higher efficacy, and a comparable incidence of adverse drug events in the observation group compared with the control group. In addition, the observation group had evidently elevated red blood cell count, hematocrit value, hemoglobin and World Health Organization quality of life scores compared with the baseline and the control group, as well as significantly higher reduced C-reactive protein, beta 2-microglobulin and interleukin-6. It can be concluded that, roxadustat is effective and safe for secondary hyperparathyroidism patients which can ameliorate anemia-related indicators and the microinflammation indicators can enhance the quality of life.
BibTeX
@inproceedings{wu2024efficacy,
  author = {Qiong Wu and Xiang‐Peng Liao and Qin Zou and Chen Ting Li and Yiyao Cui},
  title = {{Efficacy of Roxadustat for Secondary Hyperparathyroidism}},
  booktitle = {Indian},
  year = {2024},
  doi = {10.36468/pharmaceutical-sciences.spl.955},
}
Figure